RxDoctor Payments Data

Arielle Fields, MD

Internal Medicine · New Hope, PANPI 1205193448

Payments from drug & device makers

$480in general payments, 2019–2025

Across 11 payments — averaging $43.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$154
  • Novo Nordisk$126
  • Johnson & Johnson$125
  • Novartis$21
  • Lilly USA, LLC$17
  • Pfizer$14
  • plus $23 from 2 others

What the payments were for

  • Food & beverage$480100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$480 in reported general payments places this provider in the 65th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$8,152
Medicare patients
47
Services billed
110

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide134$177,605
EliquisApixaban178$164,095
OzempicSemaglutide97$145,724
JardianceEmpagliflozin152$121,436
Trelegy ElliptaFluticasone/Umeclidin/Vilanter97$90,330
MounjaroTirzepatide49$79,733
FarxigaDapagliflozin Propanediol66$61,972
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr62$44,631
Breo ElliptaFluticasone/Vilanterol62$34,308
XareltoRivaroxaban42$33,716
JanuviaSitagliptin Phosphate31$32,766
EntrestoSacubitril/Valsartan23$29,531
Albuterol Sulfate HfaAlbuterol Sulfate606$19,793
VivitrolNaltrexone Microspheres12$18,512
Tresiba Flextouch U-200Insulin Degludec27$15,887

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$17$257,338183 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta$14$173,608240 claims
PfizerEliquis$14$164,095178 claims
Novo NordiskOzempic$126$145,72497 claims
AstraZenecaFarxiga$154$61,97266 claims
Johnson & JohnsonXarelto$125$33,71642 claims
NovartisEntresto$21$29,53123 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in New Hope

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →